Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study

RATIONALE: Unlike many other COPD studies, the 4-year UPLIFT trial permitted inhaled corticosteroid (ICS) use during run-in and treatment phases. This provided the opportunity to prospectively observe the continuing effects of ICS on respiratory events in closely observed COPD population. OBJECTIVES...

Descripción completa

Detalles Bibliográficos
Autores principales: Morjaria, Jaymin B., Rigby, Alan, Morice, Alyn H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
COPD
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437199/
https://www.ncbi.nlm.nih.gov/pubmed/28255905
http://dx.doi.org/10.1007/s00408-017-9990-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437199/
https://www.ncbi.nlm.nih.gov/pubmed/28255905
http://dx.doi.org/10.1007/s00408-017-9990-8

Ejemplares similares